Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02101021
• Other study ID #: GS-US-370-1296
• Secondary ID: 2014-004480-20
• Status: Terminated
• Phase: Phase 3
• Start date: June 2, 2014
• Est. completion date: April 10, 2017

Study information

• Verified date: June 2023
• Source: Sierra Oncology LLC - a GSK company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There will be two phases to this study. The lead-in phase will evaluate the safety, pharmacokinetics, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with nab-paclitaxel and gemcitabine (nab-P + G) in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. The randomized treatment phase will evaluate the efficacy, safety, and tolerability of nab-P + G with either MMB administered at the MTD or placebo in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. Participants will continue study treatment until disease progression, unacceptable toxicity, consent withdrawal, or participant's refusal of treatment. Following treatment, participants will be followed for safety for 30 days and for survival approximately every 3 months for up to 3 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: April 10, 2017
• Est. primary completion date: April 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Presence of metastatic pancreatic adenocarcinoma plus 1 of the following:

• Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR

• Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:

• The presence of a mass in the pancreas, OR

• A history of resected pancreatic adenocarcinoma

• Measurable disease per RECIST v1.1

• Adequate organ function defined as follows:

• Total bilirubin = 1.25 x upper limit of the normal range (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) = 3 x ULN

• Absolute neutrophil count (ANC) > 1500 cells/mm^3, platelet > 100,000 cells/mm^3, hemoglobin > 9 g/dL

• Serum creatinine < ULN OR calculated creatinine clearance (CrCl) of = 60 ml/min

• Eastern Cooperative Oncology Group (ECOG ) 0 or 1

• Modified Glasgow prognostic score (mGPS) of 1 or 2 at Screening (randomized phase only)

Key Exclusion Criteria:

• Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy for pancreatic adenocarcinoma

• Currently or previously treated with biologic, small molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma

• Major surgery within 28 days of first dose of study drug

• Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent = 1 day before enrollment is acceptable)

• Known positive status for HIV

• Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier

• Peripheral neuropathy = Grade 2

• Known or suspected brain or central nervous system metastases

• Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma

• History of interstitial pneumonitis and/or require supplemental oxygen therapy

• External biliary drain

• Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Pancreatic Ductal Adenocarcinoma

Intervention

Drug:
• Momelotinib
Tablet (s) administered orally once or twice daily
• Placebo to match momelotinib
Placebo to match momelotinib tablets administered orally once or twice daily
• Nab-paclitaxel
Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
• Gemcitabine
Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Indiana University Health Goshen Center for Cancer Care	Goshen	Indiana
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Northwest Medical Specialties, PLLC	Tacoma	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Sierra Oncology LLC - a GSK company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events	Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment.; No statistical analysis was planned or performed for this endpoint.	Up to 28 Days
Primary	Randomized Treatment Phase: Overall Survival (OS)	Overall survival was defined as the time interval from first dose date of MMB to death from any cause	Baseline up to the Date of Death or Censoring, up to 3 years
Secondary	Lead-In Phase: Overall Survival (OS)	Overall survival was defined as the time interval from first dose date of MMB to death from any cause	Baseline up to the Date of Death or Censoring, up to 3 years
Secondary	Lead-In Phase: Progression-Free Survival (PFS)	Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.	Baseline up to the Date of Event or Censoring, up to 3 years
Secondary	Lead-In Phase: Overall Response Rate (ORR)	The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.	Baseline up to the Last Tumor Assessment Date, up to 3 years
Secondary	Randomized Treatment Phase: Progression-Free Survival (PFS)	Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause	Baseline up to the Date of Event or Censoring, up to 3 years
Secondary	Randomized Treatment Phase: Overall Response Rate	The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)	Baseline up to the Last Tumor Assessment Date, up to 3 years